Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Found 61 results
Author
Title
Type
[
Year
]
Filters:
First Letter Of Last Name
is
H
[Clear All Filters]
2021
Hassan-Zahraee M
,
Ye Z
,
Xi L
,
Baniecki MLynn
,
Li X
,
Hyde CL
,
Zhang J
,
Raha N
,
Karlsson F
,
Quan J
et al.
. 2021.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
.
Inflamm Bowel Dis.
Hassan-Zahraee M
,
Ye Z
,
Xi L
,
Baniecki MLynn
,
Li X
,
Hyde CL
,
Zhang J
,
Raha N
,
Karlsson F
,
Quan J
et al.
. 2021.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
.
Inflamm Bowel Dis.
Hassan-Zahraee M
,
Ye Z
,
Xi L
,
Baniecki MLynn
,
Li X
,
Hyde CL
,
Zhang J
,
Raha N
,
Karlsson F
,
Quan J
et al.
. 2021.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
.
Inflamm Bowel Dis.
Battat R
,
Hemperly A
,
Truong S
,
Whitmire N
,
Boland BS
,
Dulai PS
,
Holmer AK
,
Nguyen NH
,
Singh S
,
Casteele NVande
et al.
. 2021.
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 19(3):511-518.e6.
Battat R
,
Hemperly A
,
Truong S
,
Whitmire N
,
Boland BS
,
Dulai PS
,
Holmer AK
,
Nguyen NH
,
Singh S
,
Casteele NVande
et al.
. 2021.
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 19(3):511-518.e6.
Ma C
,
Sedano R
,
Almradi A
,
Casteele NVande
,
Parker CE
,
Guizzetti L
,
Schaeffer DF
,
Riddell RH
,
Pai RK
,
Battat R
et al.
. 2021.
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
.
Gastroenterology. 160(7):2291-2302.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Gu W
,
Wang H
,
Huang X
,
Kraiczy J
,
Singh PNP
,
Ng C
,
Dagdeviren S
,
Houghton S
,
Pellon-Cardenas O
,
Lan Y
et al.
. 2021.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
.
Cell Stem Cell.
Gu W
,
Wang H
,
Huang X
,
Kraiczy J
,
Singh PNP
,
Ng C
,
Dagdeviren S
,
Houghton S
,
Pellon-Cardenas O
,
Lan Y
et al.
. 2021.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
.
Cell Stem Cell.
Gu W
,
Wang H
,
Huang X
,
Kraiczy J
,
Singh PNP
,
Ng C
,
Dagdeviren S
,
Houghton S
,
Pellon-Cardenas O
,
Lan Y
et al.
. 2021.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
.
Cell Stem Cell.
Sedano R
,
Hogan M
,
Nguyen TM
,
Chang J
,
Zou GY
,
Macdonald JK
,
Casteele NVande
,
Hanzel J
,
Crowley E
,
Battat R
et al.
. 2021.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
.
J Crohns Colitis.
Sedano R
,
Hogan M
,
Nguyen TM
,
Chang J
,
Zou GY
,
Macdonald JK
,
Casteele NVande
,
Hanzel J
,
Crowley E
,
Battat R
et al.
. 2021.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
.
J Crohns Colitis.
Zegarra-Ruiz DF
,
Kim DV
,
Norwood K
,
Kim M
,
Wu W-JH
,
Saldana-Morales FB
,
Hill AA
,
Majumdar S
,
Orozco S
,
Bell R
et al.
. 2021.
Thymic development of gut-microbiota-specific T cells.
.
Nature. 594(7863):413-417.
Lima S
,
Gogokhia L
,
Viladomiu M
,
Chou L
,
Putzel G
,
Jin W
,
Pires S
,
Guo C-J
,
Gerardin Y
,
Crawford CV
et al.
. 2021.
Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.
.
Gastroenterology.
2020
Lukin DJ
,
Kumar A
,
Hajifathalian K
,
Sharaiha RZ
,
Scherl EJ
,
Longman RS
. 2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
.
Gastroenterology. 159(4):1541-1544.e2.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
Zhang S
,
Dogan B
,
Guo C
,
Herlekar D
,
Stewart K
,
Scherl EJ
,
Simpson KW
. 2020.
Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.
.
Antibiotics (Basel). 9(8)
Panaccione R
,
Danese S
,
Sandborn WJ
,
O'Brien CD
,
Zhou Y
,
Zhang H
,
Adedokun OJ
,
Tikhonov I
,
Targan S
,
Abreu MT
et al.
. 2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
.
Aliment Pharmacol Ther. 52(11-12):1658-1675.
2019
Battat R
,
Dulai PS
,
Casteele NVande
,
Evans E
,
Hester KD
,
Webster E
,
Jain A
,
Proudfoot JA
,
Mairalles A
,
Neill J
et al.
. 2019.
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
.
Inflamm Bowel Dis. 25(2):410-420.
Lukin DJ
,
Lawlor G
,
Hudesman DP
,
Durbin L
,
Axelrad JE
,
Passi M
,
Cavaliere K
,
Coburn E
,
Loftus M
,
Jen H
et al.
. 2019.
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.
.
Inflamm Bowel Dis. 25(4):775-781.
1
(current)
2
3
next ›
last »